Transpupillary thermotherapy for age-related macular degeneration

National Institute for Clinical Excellence
Record ID 32004000679
English
Authors' objectives:

This study aims to assess the current evidence on transpupillary thermotherapy for age-related macular degeneration.

Authors' recomendations: 1.1 Current evidence on the safety and efficacy of transpupillary thermotherapy for age-related macular degeneration does not appear adequate for this procedure to be used without special arrangements for consent and for audit or research. 1.2 Clinicians wishing to undertake transpupillary thermotherapy for age-related macular degeneration should take the following action. - Inform the clinical governance leads in their Trusts. - Ensure that patients understand the uncertainty about the procedures safety and efficacy and provide them with clear written information. Use of the Institute's Information for the Public is recommended. - Audit and review clinical outcomes of all patients having transpupillary thermotherapy for age-related macular degeneration. 1.3 Publication of safety and efficacy outcomes will be useful in reducing the current uncertainty. The Institute may review the procedure upon publication of further evidence.
Authors' methods: Overview
Details
Project Status: Completed
Year Published: 2004
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: England, United Kingdom
MeSH Terms
  • Hyperthermia, Induced
  • Macular Degeneration
  • Pupil
Contact
Organisation Name: National Institute for Clinical Excellence
Contact Address: MidCity Place, 71 High Holborn, London WC1V 6NA, UK. Tel: +44 020 7067 5800; Fax: +44 020 7067 5801
Contact Name: nice@nice.nhs.uk
Contact Email: nice@nice.nhs.uk
Copyright: National Institute for Clinical Excellence (NICE)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.